![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
BioCardia Inc | NASDAQ:BCDAW | NASDAQ | Equity Warrant |
Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.0003 | -2.31% | 0.0127 | 0.0025 | 0.0175 | 0.013 | 0.0127 | 0.013 | 5,894 | 05:00:08 |
The Company is advancing its autologous and allogenic bone marrow-derived cell therapies for three cardiovascular indications and one respiratory indication.
Third Quarter 2020 Business Highlights:
Autologous Cell Therapies
Allogenic Cell Therapies
Corporate Developments
“We are reaching critical milestones in our cardiovascular and respiratory cell therapy development programs at a time when patients are increasingly presenting with heart damage due to COVID-19,” said BioCardia CEO Peter Altman, PhD. “We believe that the clinical data supports patient benefit through paracrine mechanisms, which differs from those attempting to transform cells into new heart cells, and believe that the approach has tremendous promise to help patients suffering from severe heart and respiratory diseases.”
Third Quarter 2020 Financial Results:
Anticipated Upcoming Milestones in Q4 2020:
About BioCardiaBioCardia, Inc., headquartered in San Carlos, California, is developing regenerative biologic therapies to treat cardiovascular and respiratory disease. CardiAMP autologous and Neurokinin-1 Receptor Positive allogenic cell therapies are the Company’s biotherapeutic platforms in clinical development. The Company's products include the Helix Biotherapeutic Delivery System and its steerable guide and sheath catheter portfolio. BioCardia also partners with other biotherapeutic companies to provide its Helix system and clinical support for their programs studying therapies for the treatment of heart failure, chronic myocardial ischemia and acute myocardial infarction. For more information, visit www.BioCardia.com.
Forward Looking Statements This press release contains forward-looking statements that are subject to many risks and uncertainties. Forward-looking statements include, among other things, references to the enrollment of our clinical trials, the availability of data from our clinical trials, filings with the FDA, FDA product clearances, the efficacy and safety of our products and therapies, anticipated milestones, and other statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations. Such risks and uncertainties include, among others, the inherent uncertainties associated with developing new products or technologies, regulatory approvals, unexpected expenditures, the ability to raise the additional funding needed to continue to pursue BioCardia’s business and product development plans and overall market conditions. We may find it difficult to enroll patients in our clinical trials due to many factors, some of which are outside of our control. Slower than targeted enrollment could delay completion of our clinical trials and delay or prevent development of our therapeutic candidates. These forward-looking statements are made as of the date of this press release, and BioCardia assumes no obligation to update the forward-looking statements.
We may use terms such as “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey the uncertainty of future events or outcomes to identify these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained herein, we caution you that forward-looking statements are not guarantees of future performance and that our actual results may differ materially from the forward-looking statements contained in this press release. As a result of these factors, we cannot assure you that the forward-looking statements in this press release will prove to be accurate. Additional factors that could materially affect actual results can be found in our documents filed with the SEC, including our recent filings on Form 8-K, Form 10-K and Form 10-Q, particularly any statements under the caption entitled “Risk Factors” Therein. BioCardia expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.
Media Contact:Michelle McAdam, Chronic Communications, Inc.michelle@chronic-comm.com(310) 902-1274
Investor Contact:David McClung, Chief Financial OfficerInvestors@BioCardia.com(650) 226-0120
BIOCARDIA, INC.Condensed Statements of Operations(Unaudited In thousands, except share and per share amounts)
Three Months ended September 30, | Nine Months ended September 30, | ||||||||||||||
2020 | 2019 | 2020 | 2019 | ||||||||||||
Revenue: | |||||||||||||||
Net product revenue | $ | 8 | $ | 1 | $ | 13 | $ | 139 | |||||||
Collaboration agreement revenue | 26 | 193 | 86 | 356 | |||||||||||
Total revenue | 34 | 194 | 99 | 495 | |||||||||||
Costs and expenses: | |||||||||||||||
Cost of goods sold | — | 24 | 4 | 321 | |||||||||||
Research and development | 2,474 | 2,007 | 7,484 | 6,392 | |||||||||||
Selling, general and administrative | 1,408 | 1,390 | 4,642 | 4,460 | |||||||||||
Total costs and expenses | 3,882 | 3,421 | 12,130 | 11,173 | |||||||||||
Operating loss | (3,848 | ) | (3,227 | ) | (12,031 | ) | (10,678 | ) | |||||||
Other income (expense): | |||||||||||||||
Interest income | 1 | 17 | 19 | 53 | |||||||||||
Gain on change in fair value of redemption feature embedded in convertible notes | — | 52 | — | 52 | |||||||||||
Interest expense | (1 | ) | (112 | ) | (2 | ) | (112 | ) | |||||||
Loss on extinguishment of convertible notes | — | (521 | ) | — | (521 | ) | |||||||||
Other expense | — | (1 | ) | (1 | ) | (2 | ) | ||||||||
Total other income (expense) | — | (565 | ) | 16 | (530 | ) | |||||||||
Net loss | $ | (3,848 | ) | $ | (3,792 | ) | $ | (12,015 | ) | $ | (11,208 | ) | |||
Net loss per share, basic and diluted | $ | (0.30 | ) | $ | (0.63 | ) | $ | (1.33 | ) | $ | (2.13 | ) | |||
Weighted-average shares used in computing net loss per share, basic and diluted | 12,618,285 | 6,030,662 | 9,059,433 | 5,263,058 | |||||||||||
BIOCARDIA, INC. | |||||||
Selected Balance Sheet Data | |||||||
(amounts in thousands) | |||||||
September 30, | December 31, | ||||||
2020 (1) | 2019 (1) | ||||||
Assets: | |||||||
Cash and cash equivalents | $ | 7,392 | $ | 5,585 | |||
Other current assets | 1,198 | 793 | |||||
Property, plant and equipment and other noncurrent assets | 912 | 1,300 | |||||
Total assets | $ | 9,502 | $ | 7,678 | |||
Liabilities and Stockholders’ Equity | |||||||
Current liabilities | $ | 4,320 | $ | 4,003 | |||
Noncurrent liabilities | 1,069 | 1,305 | |||||
Total stockholders’ equity | 4,113 | 2,370 | |||||
Total liabilities and stockholders’ equity | $ | 9,502 | $ | 7,678 | |||
(1) September 30, 2020 and 2019 amounts are unaudited. December 31, 2019 amounts were derived from the audited Consolidated Financial Statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2019, filed with the U.S. Securities and Exchange Commission on April 9, 2020. |
1 Year BioCardia Chart |
1 Month BioCardia Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions